(Q38070918)

28 August 2017

1 reference

title

Coagulation and cancer: biological and clinical aspects (English)

1 reference

28 August 2017

A Falanga

1

1 reference

PubMed ID

23279708

28 August 2017

M Marchetti

series ordinal

2

1 reference

PubMed ID

23279708

28 August 2017

A Vignoli

series ordinal

3

1 reference

28 August 2017

1 February 2013

1 reference

Journal of Thrombosis and Haemostasis

28 August 2017

1 reference

28 August 2017

11

1 reference

28 August 2017

2

1 reference

28 August 2017

223-233

1 reference

Venous thromboembolism in the hematologic malignancies.

28 August 2017

1 reference

Epidemiology, risk and outcomes of venous thromboembolism in cancer

21 January 2018

1 reference

Activation of clotting factors in cancer.

21 January 2018

1 reference

Microparticles in tumor progression.

21 January 2018

1 reference

Venous thromboembolism and cancer: risks and outcomes

21 January 2018

1 reference

Cancer and venous thromboembolism.

21 January 2018

1 reference

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action

21 January 2018

1 reference

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

Assessing risk of venous thromboembolism in the patient with cancer.

21 January 2018

1 reference

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

Peripheral arterial ischemic events in cancer patients

21 January 2018

1 reference

Arterial thrombosis in ambulatory cancer patients treated with chemotherapy

21 January 2018

1 reference

Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation

21 January 2018

1 reference

Thrombotic microangiopathy with targeted cancer agents

21 January 2018

1 reference

Cancer awareness in atypical thrombotic microangiopathies

21 January 2018

1 reference

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome

21 January 2018

1 reference

Evidence-based mini-review: should all patients with idiopathic venous thromboembolic events be screened extensively for occult malignancy?

21 January 2018

1 reference

Is extensive screening for cancer in idiopathic venous thromboembolism warranted?

21 January 2018

1 reference

Acquired hemophilia in malignancy

21 January 2018

1 reference

How I treat the acquired von Willebrand syndrome

21 January 2018

1 reference

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

21 January 2018

1 reference

Thromboembolism in hospitalized neutropenic cancer patients.

21 January 2018

1 reference

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

Epidemiology of venous thromboembolism in 9489 patients with malignant glioma.

21 January 2018

1 reference

Epidemiology of cancer-related venous thromboembolism

21 January 2018

1 reference

Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.

21 January 2018

1 reference

Anticancer treatment and thrombosis.

21 January 2018

1 reference

Chemotherapy-induced thrombosis: a role for microparticles and tissue factor?

21 January 2018

1 reference

Procoagulant mechanisms in tumour cells.

21 January 2018

1 reference

Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines.

21 January 2018

1 reference

On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells

21 January 2018

1 reference

Procoagulant factors in patients with cancer.

21 January 2018

1 reference

New horizons in the analysis of circulating cell-derived microparticles

21 January 2018

1 reference

Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.

21 January 2018

1 reference

Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia

21 January 2018

1 reference

Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor.

21 January 2018

1 reference

The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia

21 January 2018

1 reference

Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN.

21 January 2018

1 reference

Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells.

21 January 2018

1 reference

Tissue factor, thrombin, and cancer

21 January 2018

1 reference

Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets

21 January 2018

1 reference

Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis

21 January 2018

1 reference

Tissue factor isoforms in cancer and coagulation: may the best isoform win.

21 January 2018

1 reference

21 January 2018

Microparticles in cancer

1 reference

Ovarian cancer cells modulate human blood neutrophils response to activation in vitro.

21 January 2018

1 reference

Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival

21 January 2018

1 reference

Impact of venous thromboembolism and anticoagulation on cancer and cancer survival

21 January 2018

1 reference

Low-molecular-weight heparin and survival in lung cancer

21 January 2018

1 reference

Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer

21 January 2018

1 reference

Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).

21 January 2018

1 reference

FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer

21 January 2018

1 reference

The protein C pathway in cancer metastasis

21 January 2018

1 reference

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM).

21 January 2018

1 reference

2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group

21 January 2018

1 reference

Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines

21 January 2018

1 reference

Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer

21 January 2018

1 reference

Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1).

21 January 2018

1 reference

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

21 January 2018

1 reference

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer

21 January 2018

1 reference

Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies

21 January 2018

1 reference

Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer

21 January 2018

1 reference

Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study

21 January 2018

1 reference

Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.

21 January 2018

1 reference

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

21 January 2018

1 reference

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management

21 January 2018

1 reference

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

Development and validation of a predictive model for chemotherapy-associated thrombosis

21 January 2018

1 reference

Prediction of venous thromboembolism in cancer patients.

21 January 2018

1 reference

Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.

21 January 2018

1 reference

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study

21 January 2018

1 reference

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period

21 January 2018

1 reference

Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer

21 January 2018

1 reference

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.

21 January 2018

1 reference

Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.

21 January 2018

1 reference

Treatment of thromboembolism in cancer patients

21 January 2018

1 reference

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

New and old anticoagulants in cancer

21 January 2018

1 reference

Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

21 January 2018

1 reference

All-trans-retinoic acid and bleeding/thrombosis.

21 January 2018

1 reference

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

21 January 2018

1 reference

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

21 January 2018

1 reference

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JTH.12075

1 reference

28 August 2017

1 reference

PubMed ID

23279708